First-in-class medication

A first-in-class medication is a pharmaceutical that uses a "new and unique mechanism of action" to treat a particular medical condition.[1] While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies and/or orphan drugs, first-in-class status itself has no regulatory effect.

Examples
Drug Class Targeted conditions Year approved

(FDA)

 Year approved

(EMA)

Inotuzumab ozogamicin

(Besponsa)

 Anti-CD22 monoclonal antibody-drug conjugate Relapsed or refractory B cell precursor acute lymphoblastic leukemia[2] 2017
Tagraxofusp

(Elzonris)

 Interleukin 3-diphtheria toxin fusion protein targeting plasmacytoid dendritic cells Blastic plasmacytoid dendritic cell neoplasm 2018 2021
Midostaurin

(Rydapt)

 Multi-target tyrosine kinase inhibitor not inhibited by the D816V cKit mutation Systemic mastocytosis, myelodysplastic syndrome, acute myeloid leukemia[3] 2017
Teprotumumab

(Tepezza)

 Anti-IGF-1R monoclonal antibody Graves' ophthalmopathy[4] 2020
Romosozumab

(Evenity)

 Anti-sclerostin monoclonal antibody Osteoporosis[5] 2019 2019
Ocrelizumab

(Ocrevus)

 Anti-CD20 monoclonal antibody Multiple sclerosis[6] 2017 2018
Ivosidenib

(Tibsovo)

 Small molecule inhibitor of isocitrate dehydrogenase 1 Acute myeloid leukemia, cholangiocarcinoma[7] 2018
Bempedoic acid

(Nexletol)

 Adenosine triphosphate-citrate lyase inhibitor Hypercholesterolemia[8] 2020 2020
Tafamidis

(Vyndaqel, Vyndamax)

 Transthyretin chaperone (stabilizer) Familial amyloid polyneuropathy and other transthyretin amyloidoses[9] 2011 2019
Voxelotor

(Oxbryta)

 Hemoglobin oxygen affinity modulator Sickle cell disease[10] 2019
Lonafarnib

(Zokinvy)

 Farnesyltransferase inhibitor Hutchinson-Gilford progeria syndrome[11] 2020
Dupilumab

(Dupixent)

 Interleukin-4 receptor alpha subunit inhibitor Asthma, atopic dermatitis, allergic diseases[12] 2017
Lasmiditan

(Reyvow)

 Selective 5-HT1F serotonin receptor agonist Migraine[13] 2019
Tazemetostat

(Tazverik)

 Selective EZH2 inhibitor Epithelioid sarcoma[14] 2020
Mounjaro

(Tirzepatide)

 GLP-1 and GIP activator adult type 2 diabetes[15] 2022

Controversy

Safety

By definition, a first-in-class drug does not have the safety evidence from analogous products that not-first-in-class drugs would have. However, a study investigating recalls and warnings in relation to first-in-class drugs approved between 1997 and 2012 by Health Canada has found that first-in-class drugs actually have a more favourable benefit-to-harm ratio.[16]

Economics

First-in-class drugs are often seen as commercially more attractive as they may tap into a market segment that has hitherto been underserved, but this may be illusory.[17] In fact, most blockbuster drugs (drugs with annual sales revenues exceeding US$1,000,000,000) were not first-in-class drugs.[17] The economic potential of a first-in-class drug, which is typically priced higher than later drugs in the same class, has been largely declining due to efforts by health insurers to restrict what specialty drugs are covered and prevent incumbency advantages.[18]

Costs

A lower number of available therapeutic options correlates with higher prices.[19] In addition, many first-in-class medications are specialty drugs and orphan drugs,[20] which means that manufacturers have to recoup development costs from a smaller market.[21] This raises ethical questions about the sustainability of the high prices on these costs.[22][23]

References
  1. Lanthier, Michael; Miller, Kathleen L.; Nardinelli, Clark; Woodcock, Janet (2013-08-01). "An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011". Health Affairs. 32 (8): 1433–1439. doi:10.1377/hlthaff.2012.0541. ISSN 0278-2715. PMID 23918488.
  2. "BESPONSA 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 2021-07-01.
  3. "Rydapt: Uses, Dosage, Side Effects, Warnings". Drugs.com. Retrieved 2021-07-01.
  4. Office of the Commissioner (2020-03-24). "FDA approves first treatment for thyroid eye disease". FDA. Retrieved 2021-07-01.{{cite web}}: CS1 maint: url-status (link)
  5. Center for Drug Evaluation and Research (2020-01-24). "New Drug Therapy Approvals 2019". FDA.
  6. "Ocrevus (ocrelizumab) Injection". www.accessdata.fda.gov. Retrieved 2021-07-01.
  7. "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Retrieved 2021-07-01.
  8. "DailyMed - NEXLETOL- bempedoic acid tablet, film coated". dailymed.nlm.nih.gov. Retrieved 2021-07-01.
  9. "Tafamidis Monograph for Professionals". Drugs.com. Retrieved 2021-07-01.
  10. "DailyMed - OXBRYTA- voxelotor tablet, film coated". dailymed.nlm.nih.gov. Retrieved 2021-07-01.
  11. "DailyMed - ZOKINVY- lonafarnib capsule". dailymed.nlm.nih.gov. Retrieved 2021-07-01.
  12. "DailyMed - DUPIXENT- dupilumab injection, solution". dailymed.nlm.nih.gov. Retrieved 2021-07-01.
  13. "DailyMed - Search Results for Lasmiditan". dailymed.nlm.nih.gov. Retrieved 2021-07-01.
  14. "Tazemetostat Monograph for Professionals". Drugs.com. Retrieved 2021-07-01.
  15. "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes". fda.gov. 13 May 2022. Retrieved 2022-06-30.
  16. Lexchin, Joel (November 2016). "How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study". Healthcare Policy. 12 (2): 65–75. ISSN 1715-6572. PMC 5221712. PMID 28032825.
  17. Schulze, Ulrik; Ringel, Michael (2013-06-01). "What matters most in commercial success: first-in-class or best-in-class?". Nature Reviews Drug Discovery. 12 (6): 419–420. doi:10.1038/nrd4035. ISSN 1474-1784. PMID 23722339. S2CID 32258945.
  18. Longman, Roger (20 July 2015). "The Shrinking Value of Best-in-Class and First-in-Class Drugs". In Vivo by Informa Pharma Intelligence. Retrieved 1 July 2021.{{cite web}}: CS1 maint: url-status (link)
  19. Kwa, Michael C.; Tegtmeyer, Kyle; Welty, Leah J.; Raney, Sam G.; Luke, Markham C.; Xu, Shuai; Kong, Betty (2020-10-01). "The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products". Archives of Dermatological Research. 312 (8): 559–565. doi:10.1007/s00403-020-02042-9. ISSN 1432-069X. PMID 32055932. S2CID 211111984.
  20. Chambers, James D.; Thorat, Teja; Wilkinson, Colby L.; Neumann, Peter J. (2017-08-01). "Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process". Health Affairs. 36 (8): 1408–1415. doi:10.1377/hlthaff.2016.1541. ISSN 0278-2715. PMID 28784733.
  21. Lieberman, Steven M.; Ginsburg, Paul B.; Patel, Kavita K. (2020). "Balancing Lower U.S. Prescription Drug Prices And Innovation – Part 1 | Health Affairs Blog". Health Affairs Forefront. doi:10.1377/forefront.20201123.804451.
  22. Herper, Matthew (2019-12-23). "The debate over America's drug-pricing system is built on myths". STAT. Retrieved 2021-07-01.{{cite web}}: CS1 maint: url-status (link)
  23. Greene, Jan (January 2017). "EpiPen Controversy Reveals Complexity Behind Drug Price Tags". Annals of Emergency Medicine. 69 (1): A16–A19. doi:10.1016/j.annemergmed.2016.10.025. ISSN 0196-0644.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.